Ciprofloxacin Adverse Reactions (Abstract)
Secondary intravenous ciprofloxacin the next day, again within 30 minutes aphasia appeared, and 70 minutes after drug withdrawal symptoms disappeared. After switching to intravenous infusion of cefazolin for seven days, no similar symptoms occurred.
[New Drugs and Clinical 1996, 15(3): 188]
Central Nervous System Stimulation: Fu Jingbo reported that a female patient experienced sweating and central nervous system stimulation after oral administration of ciprofloxacin 250mg. Three hours after medication, symptoms such as sweating, trouble, anxiety, and explosive central excitement occurred. These symptoms relieved 10 hours later. To verify, three days later, the patient took another 250mg dose, and these symptoms reoccurred.
[New Drugs and Clinical 1994, 13(2): 121]
Psychiatric Symptoms: Qin Nanping reported four cases of elderly patients who developed psychiatric symptoms after using ciprofloxacin, including spasms, hallucinations, and depersonalization. One patient with chronic bronchitis showed no response during the first three days of medication but developed psychiatric symptoms on the second day due to lung infection. The symptoms disappeared after discontinuation. Another pulmonary encephalopathy patient stopped using this product and psychiatric symptoms disappeared three days later.
[Modern Applied Pharmacy 1993, 10(2): 59]
Euphoria: Ye Jin reported in eight patients (six cases of gonococcal urethritis and two with chronic bronchitis) within 30 minutes after the use of ciprofloxacin (200mg intravenous infusion once/day), euphoria was observed. Symptoms included warmth throughout the body, a sense of excitement in two cases, and relaxation and happiness in six cases. Symptoms disappeared within 12 hours after withdrawal. All eight patients experienced euphoria again after subsequent injections.
[Chinese Journal of New Drugs 1996, 5(1): 53]
Heteroptics: Feng Shaojian reported that one patient due to pneumonia and intravenous ciprofloxacin 0.4g (60 drops/min), developed visual abnormalities on the last two days. Symptoms disappeared after stopping the product.
[Geriatrics 1995, 9(5): 204]
Acute Uveitis: Zhou Yang reported that one female patient developed acute uveitis after oral administration of ciprofloxacin due to sore throat. Symptoms included body itching, eye pain, blurred vision, mixed congestion of the bulbar conjunctiva, corneal haze, turbid aqueous humor, white fibrinous exudation, and retinal edema. After symptomatic treatment and withdrawal, itching reduced after two months, and visual acuity increased to 0.5. Two weeks later, binocular vision improved to 1.2.
[Ocular Fundus Diseases 1996, 12(1): 2]
The meeting convened by the Ministry of Health Drug Approval Council, edited by Secretary River Ice, involved participants such as Zhiqing Assistant Inspector, Zhang Aiping Director, Zhang Xiulan Deputy Director, Wei Jinhui Assistant Investigator, Guangdong Provincial Health Department Director Toshifumi, Shenzhen City Health Bureau Secretary Wang Hong, and delegates from 43 provinces, autonomous regions, and municipalities directly under the Central Government. The meeting was presided over by Secretary Silver Sheets. Director Customs and Deputy Director Hung warmly welcomed attendees at the opening ceremony. Zhiqing Assistant Visiting Members and Secretary Shao Mingli delivered important speeches on the importance of publications. River Ice Secretary praised the journal's achievement as an outstanding scientific and technological publication. Shao Mingli conveyed recent publication instructions. Zhang Aiping Director discussed developments and future work requirements. The Editorial Office summarized the 1997 extension issue. Leadership appointed focal points, directors, and coordinators and rewarded outstanding contributors. Jiangsu Secretary summarized experiences, while Shandong, Korea, and visiting wide Comrade Yang Xiaolei shared provincial and municipal focal point experiences. Deputies discussed local focal point work summaries and exchanged experiences. The leadership’s decision to establish focal points in the provinces was highly praised, pledging to raise awareness, unify thinking, and strive for leadership support to improve pharmacy rendezvous in 1998. The meeting received support and funding from Shenzhen City Health Bureau Pharmaceutical Affairs and Shenzhen Jian An Pharmaceutical Company, successfully completing its intended purpose. Sincere thanks were expressed to all contributors.